ExCella Therapeutics

ExCella Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for oncology and immunology. The company leverages its proprietary drug discovery platform to target challenging biological pathways, with a primary focus on DNA damage response (DDR) and protein homeostasis. Its lead candidate, EX-101, is a potent and selective inhibitor of Ubiquitin-specific protease 1 (USP1), currently being evaluated in clinical trials for the treatment of BRCA-mutant solid tumors. ExCella aims to provide transformative treatments for patients with high unmet medical needs through precision medicine. The company maintains operations in both the United States and China, facilitating global development of its pipeline.